Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Although chemotherapy is a first option in treatment of cancer patients, drug resistance has
led to its failure, requiring strategies to overcome it. Cancer cells are capable of switching …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Cancer is the second leading cause of death worldwide. Majority of recent research efforts in
the field aim to address why cancer resistance to therapy develops and how to overcome or …

Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading …

The presence of barriers, such as the blood–brain barrier (BBB) and brain–tumor barrier
(BTB), limits the penetration of antineoplastic drugs into the brain, resulting in poor response …

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer
(NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth …

Epithelial growth factor receptor (EGFR), a transmembrane receptor on the cell surface,
carries extracellular messages into the cell and alters the activity of the nucleus through …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …